



May 16, 2023

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE

To all stakeholders,

(Amendment) Amendment to “Presentation Material for FY2022 Business Results”

Perseus Proteomics Inc. (“the Company”) hereby announces amendment to “Presentation Material for FY2022 Business Results” announced on May 15, 2023.

1. Amended part

P4 FY2022 business results - Profit & Loss highlights

2. Amendment details

Please refer to the attachment. (Amended parts are underlined.)

*Amended presentation material for FY2022 Business Results is available on the website of the Company.

END

FY2022 business results Profit & Loss highlights

Attachment

Before amendment



(million yen)

	FY2021	FY2022	FY2022			
	Results	Forecasts	Results	vs FY2021	vs forecasts	
Sales	71	77	94	31.0%	21.9%	Ab/reagent sales Ab research support
Gross profit	67	72	86	27.7%	19.3%	
SG & A	539	776	784	45.3%	1.0%	PPMX-T003 P1 cost Adjustment of SG&A and non-operating expenses
R&D cost	308	522	494	60.3%	-5.4%	
Other	231	253	289	25.2%	14.3%	
Operating income	(472)	(703)	(697)	-	-	Foreign exchange gains
Ordinary income	(481)	(736)	(689)	-	-	
Extraordinary loss	117	116	95	-19.0%	-17.7%	Impairment loss due to restoration and capex increase
Net income	(599)	(854)	(786)	-	-	

- Sales: JPY 13 million increase Y on Y. Recovered to the pre COVID-19 level.

1

FY2022 business results Profit & Loss highlights

After amendment



(million yen)

	FY2021	FY2022	FY2022			
	Results	Forecasts	Results	vs FY2021	vs forecasts	
Sales	71	77	94	31.0%	21.9%	Ab/reagent sales Ab research support
Gross profit	67	72	86	27.7%	19.3%	
SG & A	539	776	784	45.3%	1.0%	PPMX-T003 P1 cost Adjustment of SG&A and non-operating expenses
R&D cost	308	522	494	60.3%	-5.4%	
Other	231	253	289	25.2%	14.3%	
Operating income	(472)	(703)	(697)	-	-	Foreign exchange gains
Ordinary income	(481)	(736)	(689)	-	-	
Extraordinary loss	117	116	95	-19.0%	-17.7%	Impairment loss due to restoration and capex increase
Net income	(599)	(854)	(786)	-	-	

- Sales: JPY 22 million increase Y on Y. Recovered to the pre COVID-19 level.

2